A new frontier
in weight management

Science
goes further.

SERENOVO provides access to investigational Retatrutide, a next-generation, triple-receptor peptide, through a medically supervised program.

Retatrutide is investigational. Access is subject to regulatory requirements, clinical oversight, and individual eligibility.

Conceptual visualization of a peptide ribbon approaching stylized adipose cells
The Science

A triple-pathway hypothesis.

Retatrutide is an investigational triple-receptor agonist being studied for weight management. It is designed to activate GLP-1, GIP and glucagon receptors—pathways involved in appetite, glucose metabolism and energy balance.

Published Phase 2 evidence
−24.2%Mean body-weight change48 weeks · 12 mg
100%Reached ≥5% weight loss48 weeks · 12 mg
93%Reached ≥10% weight loss48 weeks · 12 mg
83%Reached ≥15% weight loss48 weeks · 12 mg

Results shown are from the 12 mg group in a published 48-week Phase 2 obesity trial. Individual outcomes vary. Read the peer-reviewed paper

Ongoing research: Retatrutide remains investigational and additional Phase 3 studies continue. View registered trials

The Results

Progress,
illustrated.

Fictional paired profiles help visualize a supported weight-management journey. They are not patient results or predictions.

Fictional illustrative profiles and placeholder statements. These are not patients, testimonials, or predictions. Individual outcomes vary.

Published Phase 2 study
Plan preview

A considered path.
Clinical review first.

Explore two prototype support plans. This interface is illustrative and is not an offer to purchase or obtain Retatrutide.

Monthly support includes

A recurring care-pathway preview.

Monthly review pathway Ongoing clinician check-ins Cancel future plan anytime

Illustrative pricing only. Payment does not guarantee access; professional and regulatory review would be required.

Your selection

Review your plan

01 / 02

Choose an available option to continue. Customer details, delivery, applicable taxes and payment are completed securely at checkout.

Your order

No plan selected

Purchasing is not currently available.

How it works

Real science.
Real progress.

Retatrutide is being studied for how triple-receptor activity may influence appetite, metabolism, and energy balance.

  1. 1

    Get ready

    Review your study team's instructions and get your pen and supplies ready.

    Hands removing the cap from a black injection penCheck everything first. Your team can answer questions before you begin.
  2. 2

    Choose your spot

    Choose and prepare the area recommended by your study team.

    Clothed adult holding a black injection pen near the waistConfirm the location, then follow the pen instructions your team provided.
  3. 3

    Inject with ease

    Follow the pen demonstration from your study team, at your own pace.

    Hand demonstrating an injection pen against a medical training padYour team explains what to check afterward and how to dispose of supplies.
  4. 4

    Stay on track

    Record your scheduled use and questions ahead of your next check-in.

    Black smartphone displaying a green progress checklistShare how you feel so your team can review the next steps with you.
Investigational use only.

These images and steps are illustrative and are not instructions for use. Trial participants should follow their study team’s directions.

Questions, clearly answered

The essential
context.

Measured answers for an investigational therapy and a prototype experience.

Buy Now